Over the last few decades, immunotherapy has developed at a rapid rate in the treatment of cancer where neoantigens are the lates breakthrough in tumour immunotherapy. Today, it is still clear when a cancer vaccine will be made commercially available; what is the latest academic research showing us? What is the industry missing and where are we going?
Join Cancer Neoantigen Vaccines and deep dive into these questions with brightest minds in the industry to be at the forefront and unlock the new era of vaccine development. You’ll discover key research on targets and evolution, how to successfully enter global markets, and the future of personalisation and beyond.
Secure your place before booking closes midnight Friday January 26, 2023: https://bit.ly/3FcLVsL
For more information contact danielle.horney@informa.com